Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariame Layba Camara

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Sante Publique (Vandoeuvre-Les-Nancy, France)|June 23, 2025
Mariame Layba Camara, Moïse Kagbadouno, Ansoumane Kourouma, et al.
The Lancet. Global Health|April 27, 2025
Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort studyVictor Kande Betu Kumeso, Christelle Perdrieu, Caroline Menétrey, et al.
The Lancet. Infectious Diseases|December 2, 2022
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trialVictor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Sante Publique (Vandoeuvre-Les-Nancy, France)|June 23, 2025
Mariame Layba Camara, Moïse Kagbadouno, Ansoumane Kourouma, et al.
The Lancet. Global Health|April 27, 2025
Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort studyVictor Kande Betu Kumeso, Christelle Perdrieu, Caroline Menétrey, et al.
The Lancet. Infectious Diseases|December 2, 2022
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trialVictor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry, et al.
Pageof 1